Anixa Biosciences (ANIX) Total Debt (2010 - 2017)

Anixa Biosciences' (ANIX) quarterly Total Debt came in at $2.0 million in Q3 2017, down 33.33% on a QoQ basis from $3.0 million in Q2 2017.

Anixa Biosciences (ANIX) Total Debt (2010 - 2017) Analysis & Trends

Anixa Biosciences (ANIX) has 6 years of Total Debt data on file, last reported at $2.0 million in Q3 2017.

Quarterly Total Debt changed N/A year-over-year to $2.0 million in Q3 2017, while the trailing twelve-month figure through Jul 2017 was $2.0 million (changed N/A YoY) and the FY2013 annual result came in at $5.0 million, changed 0.0% from the prior year.
Total Debt slipped to $2.0 million in Q3 2017, from $3.0 million in the prior quarter.
In the past five years, Total Debt ranged from a high of $6.0 million in Q1 2017 to a low of $2.0 million in Q3 2017.
A 3-year average of $4.6 million and a median of $5.0 million in 2013 frame the typical range for Total Debt.
The widest YoY moves for Total Debt: up 0.0% in 2013, down 0.0% in 2013.
Tracing ANIX's Total Debt over 3 years: stood at $5.0 million in 2013, then changed by 0.0% to $5.0 million in 2014, then slumped by 60.0% to $2.0 million in 2017.
The last three Total Debt figures came in at $2.0 million (Q3 2017), $3.0 million (Q2 2017), and $6.0 million (Q1 2017), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.29 Bn	78.30 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.17 Bn	59.98 Bn	1.37 Bn	-
4	Moderna	61.38 Bn	56.24 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.18 Bn	37.09 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	30.99 Bn	27.68 Bn	992.69 Mn	-
7	BioNTech SE	28.45 Bn	10.05 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	9.34 Bn
10	Anixa Biosciences	122.95 Mn	122.95 Mn	-	-

Download Data